StemCell Therapy

NEW YORK--(BUSINESS WIRE)-- Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology, and AdhereTech, a pioneer and leading provider of smart devices that connect patients to care with real-time interventions, announced their partnership to provide advanced, data-driven digital health technology solutions, focusing in oral oncolytic agents providing real-time integrated access to care for cancer patients to precision oncology drugs and leading-edge clinical trials. Both companies were recognized in the 2022 NYC Digital Health 100 which showcases the most exciting digital health companies in the New York region.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005289/en/

Massive Bio and AdhereTech, two of NYC Digital Healths 100 most promising start-ups, announce a partnership to provide integrated access to precision oncology care for cancer patients. (Photo: Business Wire)

Massive Bio and AdhereTech have committed to combining their products and services to offer global, comprehensive solutions to measure, analyze and monitor precision oncology medication adherence for patients participating in clinical trials and those prescribed commercially available treatments. Both companies currently are contracted with leading pharmaceutical companies and major specialty pharmacies. Their work with payers, pharmacies and pharmaceutical companies to develop adherence programs utilizing device generated data to optimize processes and improve cost-effective measures for specialty drug and clinical trial programs that may save the industry hundreds of billions of dollars per year.

While the conversation around digital health and pharma has expanded well beyond from adherence, in oncology it provides the link between cost-effective treatments, and an opportunity to prioritize clinical trials when most appropriate mentioned Selin Kurnaz, CEO and Co-Founder of Massive Bio. Even modest improvements can lead to huge cost savings for payers and the pharmaceutical research industry, while allowing streamlined access in real time to effective on-label precision oncology treatments. It is a win-win situation for all stakeholders, from patients to specialty pharmacies, payers, and the commercial and cancer research ecosystem. AdhereTech is one of the few companies that is successfully achieving those goals, and we are excited about this collaboration.

With over 13,000 active cancer clinical trials in the US at any given time, and dozens of biomarkers and precision oncology molecules under study, Massive Bio aims to use AI and patient-centric concierge services at scale to reach cancer patients globally and accelerate the oncology research and development infrastructure. Massive Bio had recently announced the launch of its NASA-style Oncology Clinical Trial Command Center (OCTCC) to disrupt and accelerate trial enrollment, and also the launch of its 100K Cancer Clinical Trial Singularity Program aimed at matching 100,000 cancer patients in real-time to cutting-edge clinical trials using its Massive Bios AI-based technology, website and apps across iOS and Android platforms, expanding their presence as a global company with country-level success in 12 markets.

AdhereTech is a leader in medication programs, providing commercialized digital solutions to measure and manage medication adherence in a variety of settings, including academics, clinical trials, and commercially prescribed treatments. It develops and produces treatment management solutions utilizing smart devices with integrated cellular technology that, seamlessly, connects patients in real time to confirm when patients take their medication and provides two-way communications to ensure dosing regimens are followed and reports and escalates the reasons for and missed doses.

The Aidia System creates personalized patient support with specialty pharmacies and healthcare teams, enabling timely health interventions when they are necessary, and clinical trials can benefit from those key interventions, said Chris OBrien, Chief Executive Officer of AdhereTech. Upon learning of Massive Bios traction in the oncology space, and the opportunities of using our Aidia System, expansive network, and real-world data to help patients, physicians and the cancer research industry at a technology enabled scale, it made absolute sense to explore and operationalize this partnership.

Our AI-enabled clinical trial and precision oncology therapy-finding technology works at its best when paired up with real-time patient-reported insights said Arturo Loaiza-Bonilla, M.D., Co-Founder of Massive Bio. By leveraging real-time data from AdhereTechs Smart Adherence System in combination with our SYNERGY-AI cancer trial matching platform, we can identify key opportunities for clinical trial enrollment, while also optimizing medication adherence and access in both precision oncology care, and cancer research.

At AdhereTech, we strive to bring data, analytics and new technologies to market to serve patients and life science companies with better resources in the vital clinical research and treatment realms said Gregory Gallo, Chief Revenue Officer of AdhereTech. Were excited to partner with a cutting-edge solutions provider in the critical oncology therapeutic category. Collaborating, integrating technology and resources will serve to streamline patients journeys and achieve more consistent engagement, enhance care and ultimately improve outcomes and scientific advances, added Gallo.

About AdhereTech

AdhereTech is a privately held digital health company headquartered in New York, NY, and is the leading provider and pioneer of smart devices that connect patients to care via real-time interventions. AdhereTech partners with pharmaceutical manufacturers, specialty pharmacies and healthcare teams with the mission of using technology informed by insights into human behavior to improve health outcomes. Its Aidia SystemTM is a proven, integrated technology-based adherence solution that empowers patients and healthcare teams to achieve optimal medication success. For more information, please visit us at http://www.adheretech.com. You can also follow us on LinkedIn and Twitter, @AdhereTech.

About Massive Bio

Massive Bios (https://massivebio.com/) mission is to provide access to clinical trials for every cancer patient regardless of his/her location and/or financial stability. Massive Bio is an AI-driven platform connecting cancer patients and their oncologists to bio-pharmaceutical clinical trials, yielding profound improvement in access and match rates, leading to faster drug development timelines, and creating a novel oncology data ecosystem for improved protocol design and real-world insights. Massive Bio controls the patient enrollment value chain starting with patient identification, following with AI-based virtual pre-screening outside the site, and resolving last mile issues for clinical trial enrollment. While improving cancer patients lives, Massive Bio serves over two dozen pharmaceutical companies, contract research organizations (CROs) and hospital networks. In addition, Massive Bio has been awarded an SBIR contract by the National Cancer Institute (NCI) to develop and characterize its Deep Learning Clinical Trial Matching System (DLCTMS), Contract No. 75N91020C00016. Selected to the "Digital Health 100" by New York City Health Business Leaders, Massive Bio provides oncology dedicated patient recruitment, site selection, real-world data services, and AI-based trial prescreening services to its enterprise customers. Massive Bio was founded in 2015, is headquartered in NYC, and is privately funded by strategic and financial investors. Follow Massive Bio on Twitter, LinkedIn, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005289/en/

The rest is here:
AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions...

Less than 2 weeks ahead of the American Diabetes Association 82nd Scientific Sessions, new data from the Diabetes Prevention Program Outcomes Study (DPPOS) provided insight into 21 years of follow-up from more than 3,200 adults with prediabetes. As with previous data releases from the program, the new data drew a lot of attention and, for many, it was because the results fly in the face of conventional wisdom: neither lifestyle interventions nor metformin reduced the cardiovascular disease risk among these patients.

With both of these approaches proven to provide benefit for reducing risk of type 2 diabetes, metformin and lifestyle interventions have established themselves as integral parts of treatment algorithms for many patients with diabetes. However, in recent years a new emphasis has been placed on not only addressing subpar glycemic control in patients with diabetes, but addressing the inherent cardiovascular and renal risk in these patients through use of newer agents, such as GLP-1 receptor agonists and SGLT2 inhibitors.

With this in mind, Endocrinology Network asked a trio of experts in diabetes and cardiometabolism what they thought of the recent data from DPPOS and whether or not it is time to shift away from metformin being a first-line therapy for patients with type 2 diabetes towards a newer agent or agents. The responses of these experts, Juan Frias, MD, of National Research Institute, W. Timothy Garvey, MD, of University of Alabama at Birmingham, and Hiddo Heerspink, PharmD, PhD, of Groningen University in the Netherlands, can be found below.

Juan Frias, MD: That is a great question. My answer would be that metformin is very inexpensive, and oftentimes free, and it is very effective in lowering the glucose. In your patients, particularly your patients with very high glucose, usually you get a greater reduction, but that's known for any medication that can do very well from a glycemic perspective with metformin.

What I would say is that we should not use metformin and delay the use of those agents, such as a GLP-1 or an SGLT2 inhibitor, in patients who are appropriate and need those agents. So, don't use metformin, to the exclusion of using the other agent. I think it could be certainly be an adjunct in a lot of patients because it does improve clearly improves glycemic control. Again, it's generic, it's inexpensive, and I would say that it's going to continue to be used. Sulfonylureas continued to be used, and I certainly think those should be phased out before metformin gets phased out.

So, we need to just make sure as the guidelines tell us, irrespective of the HbA1c and irrespective of metformin use, that patients with atherosclerotic cardiovascular disease who are at very high risk should be using GLP-1 receptor agonists or SGLT2 inhibitors with proven cardiovascular benefit. In patients with heart failure, they should be using an SGLT2 inhibitor. In patients with chronic kidney disease, an SGLT2 inhibitor and often times a combination of SGLT2 inhibitor and GLP-1 receptor agonist and I think metformin is fine to include there. What you don't want to do is be on metformin for 1-2 years and not add those other agents.

W. Timothy Garvey, MD: Well, that's a good question. But there's a subanalysis of the DPP data looking at patients that lost 10% or more of their body weight, and this subgroup did have a decrease in MACE outcomes: myocardial infarction, non fatal stroke, and this composite cardiovascular outcome measure. So, this data suggests that it boils down to achieving sufficient weight loss to achieve cardiovascular protection. We don't have these data from these weight loss medications at this point.

There is a study called SELECT that's ongoing with semaglutide 2.4, and patients without diabetes, but, again, we won't have those data probably for a couple of years. I also think there is a cardiovascular outcomes trial in process for patients with diabetes for tirzepatide. Again, we're just awaiting those data, but if we can show that these medications, together with lifestyle interventions, achieved sufficient weight loss to put them in the range where we can expect to see cardioprevention, that could be and that should be a game-changer.

I think in terms of how we think about these patients, we need to help increase the access of patients to these evidence-based therapies, which currently for obesity is somewhat limited. Maybe, with these data showing the degree of weight loss, how this weight loss translates in to the prevention, or treatment of obesity related complications, I think payers and healthcare systems are going to be more amenable to making these therapies these interventions available to patients.

Hiddo Heerspink, PharmD, PhD: I think it's time to think about prevention of complications of type 2 diabetes or prediabetes. Metformin is a fantastic drug to reduce hyperglycemia, but the outcome data, as you mentioned, is limited. We have fantastic outcome data with SGLT2 inhibitors and fantastic outcome data with GLP-1 receptor agonists.

So, from my perspective, it's really time to rethink our approach for the treatment and the sequencing of tracks. As I've already mentioned, I believe it's about the prevention of outcomes. It's not also prevention of diabetes or new-onset diabetes and we have data from the SGLT2 trials with nondiabetic patients that SGLT2 inhibitors reduced new onset diabetes by over 33%.

So, it's really important to take that into consideration and rethink our approach. Our approach has been traditionally on the timing of when drugs came to market and we have always added all new drug but now with many new drugs showing cardiovascular benefits, it's time to think about which combination for which patients. So, we are really heading into an area of personalized medicine I've received the near future.

These transcripts have been edited for length and clarity.

Original post:
Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network

DCISionRT with Novel Residual Risk Subtype Identifies Patients Who May Not Benefit from ET after Surgery and Radiation

LAGUNA HILLS, Calif., June 7, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). The new information was presented in an oral abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL.

The results of the study demonstrated that after breast conserving surgery (BCS) patients in the DCISionRT elevated risk group had a significant risk reduction from endocrine therapy (ET), while those patients in the DS low risk group did not have a significant risk reduction from ET.

"For the first time, physicians have access to an enhanced method of identifying which patients may have a significant or minimal benefit from adjuvant endocrine therapy based on individual tumor biology," said Pat Whitworth, MD, FACS, ASCO Presenter and Breast Surgical Oncologist Director, Nashville Breast Center; Associate Professor, University of Tennessee; and Managing Partner TME. "The results are meaningful and support a more tailored treatment plan for our DCIS patients."

DCISionRT stratified patients as low risk, neither adjuvant ET nor radiation therapy (RT) resulted in reduced 10-year ipsilateral breast recurrence (IBR) (5.6% BCS+ET vs BCS alone). Patients in the elevated risk group, benefited from adjuvant ET as well as RT.

"We are excited to share this unique data demonstrating the expanded utility of DCISionRT to guide personalized treatment decisions for DCIS patients," says Dan Forche, President and CEO of PreludeDx. "As precision medicine becomes the new standard of care, we are committed to continuous innovation to improve healthcare outcomes for early-stage breast cancer patients, clinicians and the healthcare system."

About DCISionRT for Breast DCIS

DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from the University of California San Francisco, and built on research that began with funding from the National Cancer Institute, enables physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman's individual tumor biology along with other pathologic risk factors and provide a personalized recurrence risk. The test provides a Decision Scorethat identifies a woman's risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk. PreludeDx is a Fjord Ventures portfolio company.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.

Media Contact

Investor Contact

Cory Dunn

Andrew Wade

760.705.7464

949.600.8925

cdunn@preludedx.com

awade@preludedx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/preludedx-presents-new-dcisionrt-data-on-the-effectiveness-of-endocrine-therapy-in-dcis-patients-at-the-asco-2022-annual-meeting-301562715.html

SOURCE PreludeDx

View post:
PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - 69News WFMZ-TV

Hyderabad, June 6 (UNI) Technology Business Incubator Birla Institute of Technology and Science (BITS) Pilani, Hyderabad has collaborated with American Association for Precision Medicine (AAPM) and World Investors and Entrepreneurs Summit (WISE) to conduct the 'Precision Medicine 2022' event at its campus here on Tuesday with the theme of Precision Medicine, Artificial Intelligence (AI) & the Future of Personalized Health care.This event brings together top experts and thought leaders in precision medicine, life science, biotech, MedTech, and pharma. It is designed to bring the community together and serve as a leading forum for new medical breakthroughs and cutting-edge basic, translational, and clinical research, BITS Pilani said in a release here on Monday.

To fulfill this vision, we will be showcasing thought leaders involved in innovative research, developing new capabilities, and developing technological interventions to speed up the delivery of personal health. The biggest Precision Medicine event will also showcase new solutions to clinical and omics data collection, transfer, storage, analysis, security, and design/implement new Big Data Solutions and AI.UNI KNR CS1206

Here is the original post:
BITS Pilani Hyderabad to conduct 'Precision Medicine 2022' event tomorrow - United News of India

ReportLinker

Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares. - Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, June 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Laboratory Information Systems (LIS) Industry" - https://www.reportlinker.com/p05957217/?utm_source=GNW - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year - Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026

- LIS is advanced software that stores and manages data in laboratories, and is used for sending test orders, recording laboratory test results, sorting data in databases. These platforms are widely used by clinics, hospitals and diagnostic laboratories to maintain data related to tests and medical history of patients, track data quality and send laboratory test orders. The demand for LIS is driven by their ability to enhance productivity, allow precise and accurate diagnosis, reduce diagnostic errors and improve patient satisfaction. The global market is poised to register significant growth in the future due to various factors such as rising incidence of chronic diseases, the huge volume of test data obtained from clinical testing, the need for enhanced lab automation and efficiency. The global market for these systems is also propelled by increasing adoption of digital solutions to store, retrieve and maintain data in real-time. These systems are offered by sophisticated analytic tools to deal with healthcare issues and improve overall productivity. The market is gaining from the need to reduce diagnostic errors, use of LIS to boost laboratory workflow efficiency, and incorporation of these systems with EHR systems. However, factors such as high maintenance cost, shortage of skilled professionals, and need for specialized laboratories remain key challenges for the market. On the other hand, huge investments by governments in LIS, increasing need for customized systems with data security functions and availability of advanced platforms are expected to present new growth avenues for the market. Rising adoption of laboratory automation and advances in R&D, particularly in biotechnology and pharmaceutical industries, are slated to push the market growth.

- Amid the COVID-19 crisis, the global market for Laboratory Information Systems (LIS) estimated at US$1.7 Billion in the year 2022, is projected to reach a revised size of US$2.4 Billion by 2026, growing at a CAGR of 9.2% over the analysis period. Standalone, one of the segments analyzed in the report, is projected to grow at a 6.6% CAGR to reach US$1.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Integrated segment is readjusted to a revised 12.2% CAGR for the next 7-year period. This segment currently accounts for a 41.9% share of the global Laboratory Information Systems (LIS) market. Based on product, standalone LIS segment is poised to hold a major share of the market during the analysis period, owing to key factors such as user-friendly nature, enhanced data security, affordability, and ability to work offline. As standalone LIS are not part of a software package, their ability to work offline augments its implementation. Technological innovations is also expected to further boost demand for standalone LIS. Integrated LIS is projected to witness faster growth during the analysis period. Against a backdrop of rising adoption of EMR, healthcare institutions are striving to achieve interoperability and standardization. This in turn spurred the shift from best-of-breed or standalone LIS to deployment of enterprise-wide integrated LIS. Integrated LIS lower dependencies on interfaces, vendor contracts, and total cost of ownership. The U.S. Market is Estimated at $825.5 Million in 2022, While China is Forecast to Reach $148.5 Million by 2026

- The Laboratory Information Systems (LIS) market in the U.S. is estimated at US$825.5 Million in the year 2022. The country currently accounts for a 52.9% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$148.5 Million in the year 2026 trailing a CAGR of 12.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR while Rest of European market (as defined in the study) will reach US$166.8 Million by the close of the analysis period. The US is at the forefront of adoption of LIS systems and dominates the global market, owing to favorable reimbursement policies in the country, for pathology procedures. The region is exhibiting strong gains on account of technological advancements and expansion of the healthcare sector, encompassing clinical research laboratories and diagnostic centers. Europe is another lucrative market for LIS. Developed countries like Germany for instance, are increasingly embracing automation in healthcare for reducing need for workforce. Healthcare providers in such markets are eagerly focusing on deploying automation like LIS for providing quality care to patients. The LIS market in Asia-Pacific, mainly China, is projected to post the fastest growth rate in the coming years due to extensive penetration of these systems in the region on account of surge in personalized medicine demand in the country and also rapid propagation of cloud LIS. Select Competitors (Total 254 Featured) Cerner Corporation Cirdan Comp Pro Med, Inc. CompuGroup Medical AG Margy Tech Pvt Ltd. McKesson Corporation Meditech Orchard Software Corporation Soft Computer Consultants Inc. Sunquest Information Systems, Inc. XIFIN Inc.

Read the full report: https://www.reportlinker.com/p05957217/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession The Never-Ending ?Race? Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond? Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic EXHIBIT 1: Time is of Essence! What We Know So Far - ?Vaccine Efficiency Against New Strains? With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them? EXHIBIT 2: With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness: Number of Booster Doses Administered Per 100 People by Country as of December 2021 With IMF Making an Upward Revision of Global GDP for 2022, Companies Are Bullish About a Continuing Economic Comeback Despite a Prolonging Pandemic EXHIBIT 3: A Strong Yet Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections: (Real GDP, Annual % Change) for 2020 through 2022 Overwhelming COVID-19 Testing Volumes Elevate Demand for Laboratory Information Systems EXHIBIT 4: Laboratory Information Systems (LIS) - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for 254 Players Worldwide in 2022 (E) A Prelude to Laboratory Information Systems (LIS) Functions of an Effective LIS Global Laboratory Information Systems Market to Witness Rapid Growth Standalone LIS Holds Major Share Services Segment Dominates the LIS Market, Software to Witness Higher Growth during the Forecast Period On-Premise LIS Holds Major Share Due to Customization Benefits Cloud-based LIS Model to Grow in Prominence due to Many Benefits Offered over Traditional, On-Premise Models US Holds Clear Edge over Other Regions, Asia-Pacific to Exhibit Fastest Growth RECENT MARKET ACTIVITY

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS Introduction of Advanced Technologies Fuel Demand for Laboratory Information Systems Digitization of Healthcare Drives Integration of LIS Accelerating Pace of Digital Pathology Increase Adoption Increasing Concerns Pertaining to Data Integrity Fuel Demand for Laboratory Information Systems Introduction of Stringent Data Protection Guidelines Propel Demand for Laboratory Information System Software Use of Easy to Integrate Laboratory Information Systems Gain Momentum Artificial Intelligence Gains Prominence EXHIBIT 5: AI Spending in Healthcare & Life sciences in US$ Million for Years 2020 & 2025 Burgeoning Population and Rising Incidence of Chronic Diseases: A Key Market Driver for LIS EXHIBIT 6: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others EXHIBIT 7: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 EXHIBIT 8: Breakdown of Total Number of Cancer Cases by Cancer Site: 2020 EXHIBIT 9: Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for Laboratory Information System/LIS market EXHIBIT 10: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 Growing Adoption of Laboratory Automation Drives the Need for LIS Rise of Laboratory 4.0 to Spur the Adoption of LIS EXHIBIT 11: World Laboratory Automation Market in US$ Billion for Years 2018, 2020, 2022, 2024 & 2026 Laboratory Information Systems Gain Traction amidst Growing Need to Enhance Workflow Efficiencies and Reduce Costs Rise in Molecular Testing Volumes to Elevate Demand EXHIBIT 12: Global Genetic Testing Market in US$ Million: 2015, 2020, & 2025 Improving Healthcare Expenditure to Turbo Charge Future Growth of the Market EXHIBIT 13: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023 EXHIBIT 14: Elderly Healthcare Expenditure as a % of GDP Need to Improve Diagnostics Accuracy Increasing Popularity of Enterprise LIS Rise in Consolidation of Healthcare Providers Creates Need for Robust and Comprehensive LIS Growing Emphasis on Personalized Medicine to Support Growth EXHIBIT 15: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025 Rise in Investment in R&D Activity to Spur Growth Shortage of Trained Professionals Hinders Adoption Rate

4. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Laboratory Information Systems (LIS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Laboratory Information Systems (LIS) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Standalone by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for Integrated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Integrated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Integrated by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for On-Premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for On-Premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for On-Premise by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for Cloud by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Cloud by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Cloud by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospital Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Independent Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES Laboratory Information Systems (LIS) Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) Market Analytics Table 31: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 34: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 37: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 40: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

CANADA Table 43: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 46: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 49: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 52: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

JAPAN Table 55: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 58: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 61: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 64: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

CHINA Table 67: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 70: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 73: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 76: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: China Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: China 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

EUROPE Laboratory Information Systems (LIS) Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) Market Analytics Table 79: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Laboratory Information Systems (LIS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027

Table 82: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 85: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

The rest is here:
Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026 - Yahoo Finance

Medical Nutrition Market: Complementarity of Pharmacology & Nutrition to Augur Well for Growth

As old health rules are overturned, a physiological approach that starts from health in place of disease is gaining high emphasis. Hippocrates quote, Let food be thy medicine and medicine be thy food has been put into practice, as individuals are considering medical nutrition and food for enhancing health and treating disease, despite the developments procured in the field of medical science.

Get Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1704

The idea of disease prevention to avoid or simplify complicated therapeutics is supported by the convergence of the pharmaceutical and food industry. In the past years, literatures have stated that the gap between nutrition science and pharmacology has been narrowing, a progress stirred by both disciplines. The only substances considered pharmacologically active in the past were drugs. Progressing on these terms, medical nutrition, the new treatment pattern entails on the fact that nutrients can have an intense effect on metabolic, immunological and other pathophysiological processes of unhealthy patients.

TMR, in its new research study, reveals compelling insights into the medical nutrition space, to assist readers with data-driven decision making. According to the TMR study, revenues from the medical nutrition market closed in on a valuation of over US$ 13,000 Mn in 2018. This growth is attributed to the growing awareness of chronic diseases among consumers coupled with the various initiatives and programs commenced for the effective prevention and control of these diseases. This has led to the growing inclination towards medical nutrition supplements.

Developments in biotechnology has further resulted in the revolution of the medical nutrition market as key manufacturers are concentrating on research and development of improved and personalized medical nutrition offerings. Moreover, the development of disease-specific specialized solution for the medical nutrition markets is also observed, particularly in the developed economies.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1704

From industry giants to first-movers, enterprises have long been in mercy of revolutionizing industry trends. Key trends shaping the medical nutrition landscape are discussed below.

Get COVID-19 Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1704

The digestive wellness trend embodies the increasing awareness around new ingredients, nutritional products which are based on the public health recommendations and science. This is led to the reduction of sugar content of foods. According to reports, a large part of the consumer base prefers the consumption of health-improving ingredients through food, as consumers care about nutrition with which they gain a control over their health and lifestyle. Foods that help reduce the gastrointestinal symptoms including the free-from foods, added-benefits ingredients,fermented foods, prebiotics, andprobioticsare gaining focus with this trend.

Driven by key developments in technology along with the continual progress attained by the field of science, the personalized medical nutrition has become much more than just a concept. Medical nutrition solutions providers are incorporating multidisciplinary approach to set up centers that focus on development of nutritional products that cater to specific needs. The future of personalized medical nutrition is cited to be fully individualized backed with constant monitoring of personalized information including gut bacteria, biomarkers or genes.

Explore More Related Reports:

Vegetable Oils Market https://www.transparencymarketresearch.com/vegetable-oil-market.htmlHerbal Extracts in Nutraceuticals Market https://www.transparencymarketresearch.com/herbal-extracts-in-nutraceuticals-market.htmlMoringa Supplements Market https://www.transparencymarketresearch.com/moringa-supplements-market.htmlChelated Minerals Market https://www.transparencymarketresearch.com/chelated-minerals-market.htmlLivestock Cake Market https://www.transparencymarketresearch.com/livestock-cake-market.html

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision

Contact:

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:https://www.transparencymarketresearch.com/

View post:
Medical Nutrition Market Promising Growth Opportunities and Forecast 2027 - Digital Journal

Published on June 7, 2022

Bengaluru: A new whitepaper, commissioned by Lenovo & Intel, led by IDC, highlights key challenges and drivers transforming the healthcare landscape across Asia Pacific. Titled Leveraging High-Performance Compute Infrastructure to Address the Genomic Data Challenge in Life Sciences, the paper underlines humanitys greatest challenges where genomics research-led intervention could impact significantly. A key highlight from the paper states that while the pandemic-led acceleration in innovation has given a boost to the Indian healthcare sector, genomics high-performance computing (HPC) infrastructure that is key to drug/vaccine discovery & precision medicine, is still at a startup stage for nearly 57% of surveyed organizations in India. This trend is also seen across a few other APAC regions surveyed: Japan and Korea lead in having advanced (3+ years) infrastructure.

The survey was conducted across 150 pharmaceutical and biotech companies across five key markets in Asia India, Singapore, Thailand, Japan, and Korea.

Genomics and Humanitys Greatest Challenges:

When it comes to solving biggest challenges facing societies and mankind, 40% of decision makers in India are certain that genomics is fundamental to developing a precision medicine strategy to treat chronic illness, rare diseases, and lifestyle disorders. Unsurprisingly, 33% of the organizations surveyed across Asia Pacific mirror this drift, followed by 21% who believe genomics can improve development of drugs and vaccines which is also a priority for 20% organizations in India.

Distinctive aspects discovered in the white paper point to the expansive potential of genomics. One being able to impact hunger and malnutrition, which has been ranked as the second greatest challenge across 40% of decision makers. According to 30% of surveyed leaders in India, genomics could also be a game-changer in helping to improve the environment as climate change continues to be a serious cause of concern.

Commenting on this, Sinisa Nikolic, Director and Segment Leader, HPC & AI, AP, Lenovo ISG, said, The volume and type of genomics data generated is unimaginable and to make accurate decisions based on this data requires huge computing power. This gets even more difficult with complex and unscalable solutions that were found to be cautious factors for 50% of organizations in India looking for genomics solutions.

Increasing Genomic Workloads and Storage Capabilities:

The trend towards developing niche, high-value personalized health solutions is expected to boom as 83% of organizations in India anticipate their annual genomics workloads to grow more than 10% over the next two years. Similarly, for 80%, the annual spend on data storage and compute is likely to increase more than 10% in the two-years period.

Sumir Bhatia, President AP, Lenovo ISG, said, One size doesnt fit all, whether at frontend healthcare delivery or backend IT infrastructure. To catchup with the ever-growing data, the required infrastructure setup can immensely add to the capital and operational expenditure. We expect this to be a critical challenge for organizations in India working to enhance their HPC infrastructure. This is where pay-as-you-go models like Lenovo TruScale become crucial so businesses of all sizes can scale up & down as required, and easily manage their operational expenditure to address humanitys greatest challenges.

The growing storage requirement predictions could add to the existing cost burdens for 33% of organizations who are currently spending more than $1M annually on data compute, storage, and maintenance & services. Even with the challenges around scalability, flexibility, and costs, nearly half (46.7%) of the respondents are not looking to acquire new solutions to transform their HPC landscape. Surprisingly, similar feedback was given by 50 percent of the leaders in Asia.

Recognizing IT Challenges and Accelerating Genomics Transformation with HPC:

With a growing focus on making precision medicine a reality, nearly 47% of decision-makers in Indias genomics industry feel that, with the high velocity at which genome data is generated, the lack of computing power to analyze it becomes the biggest infrastructural challenge for genome sequencing. Delving further into the challenges, 40% of the respondents ranked multi-dimensionality of data as the second-big IT challenge.

Close to 97% of respondents in India are using high-performance workstations and nearly 23% also use laptops for data visualization. Interestingly, 46% are using 3D augmented reality/virtual reality (AR/VR) solutions, indicating a growing shift toward immersive visualization techniques, complemented by deep learning to enable molecular modeling and simulations.

A major challenge for researchers is the time taken to process a single genome. Fortunately, solutions like Lenovo Genomics Optimization and Scalability Tool (GOAST) reduce the time to process a single human genome from 150 hours to less than 48 minutes. This enables researchers to quickly map a cohort of people instead of spending time analyzing a single genome. HPC supports high-throughput volumes to accelerate the speed of analysis, whereas AI helps make sense of the difference between genomes. This is why we are seeing GOAST being preferred by nearly 37% of organizations in India and expecting it to grow tremendously over the next few years. Sinisa Nikolic added.

In the entire context of genomics data, cyberthreats are a key challenge for only 3% of the organizations in India, while more than 80% feel strongly of their cybersecurity strategy indicating it as lowest amongst the hurdles.

Go here to read the rest:
57% of Organizations in India are at the Startup Stage of Genomics High-Performance Computing Infrastructure - APN News

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

myCare-024-04 Study Finds Cellworks Personalized Biosimulation Provides Superior OS and PFS Predictions for GBM Patients Beyond Standard Clinical Factors

CHICAGO--(BUSINESS WIRE)--

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-024-04 study, which demonstrate that the Cellworks Singula Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) and Progression-Free Survival (PFS) for newly diagnosed Glioblastoma Multiforme (GBM) patients. In this study, Singula TRI provided patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies and provided predictive value beyond physician-prescribed therapy, patient age, patient sex, and MGMT methylation status.

The results from the myCare-024-04 clinical study were featured in a poster presentation with comments from Dr. Manmeet Ahluwalia, M.D., M.B.A., Chief of Medical Oncology, Chief Scientific Officer and Deputy Director at Miami Cancer Institute, part of Baptist Health South Florida, at the 2022 ASCO Annual Meeting June 3-7th during the Central Nervous Systems Tumors Session and available online as Abstract 2053.

The molecular heterogeneity of GBM is a key driver for the inconsistent therapy response rates that we see in brain cancer patients and makes the disease difficult to treat, said Patrick Wen, MD, Director, Center for Neuro-oncology, Dana-Farber Cancer Institute; Professor, Neurology, Harvard Medical School; and Co-Principal Investigator for the myCare-024-04 clinical study. But by using a patients NGS data and Cellworks Singula to biosimulate their individual therapy responses, we can potentially improve the ability to select the most effective therapy for each GBM patient and positively effect clinical outcomes for brain cancer patients.

The significant differences in treatment response among GBM patients necessitates moving beyond population-based treatments to personalized multi-gene therapy predictions, said Dr. Manmeet Ahluwalia, M.D., M.B.A., Chief of Medical Oncology, Chief Scientific Officer and Deputy Director at Miami Cancer Institute, part of Baptist Health South Florida; and Co-Principal Investigator for the myCare-024-04 clinical study. Using Cellworks Singula TRI, we can simulate the molecular effects of cell signaling, drugs and radiation on patient-specific in silico diseased cells prior to treatment and then identify the magnitude of disease control and survival for specific anti-tumor strategies. The findings from using this approach in the myCare-024-04 study suggest that biosimulating guideline GBM therapies for newly diagnosed GBM patients can positively effect clinical outcomes.

The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. The platform is powered by the groundbreaking Cellworks Computational Omics Biology Model (CBM), a network of 7,000+ human genes, 30,000+ molecular species and 100+ signaling pathways. As part of the biosimulation process, personalized disease models are created for each patient using their cytogenetic and molecular data as input to the Cellworks CBM. The Cellworks platform analyzes the impact of specific therapies on the patients personalized disease model and generates a Singula biosimulation report with Therapy Response Index (TRI) scores from 0 to 100 that predict the efficacy of specific chemotherapies.

myCare-024-04 Clinical Study

Background

In this study, the Cellworks Singula Therapy Response Index (TRI) was used to prospectively predict the Overall Survival (OS) and Progression-Free Survival (PFS) in a retrospective cohort of 270 IDH wildtype GBM patients from the Cancer Genome Atlas (TCGA) with known clinical outcomes treated with physician prescribed therapies. The cohort included 162 males and 108 females with a median age of 57.5 years.

Methods

A mechanistic mulit-omcis biology model created for each patient using comprehensive genomic inputs allows biosimulation of downstream molecular effects of cell signaling, drugs and radiation on a patients personalized in silico disease model. Stratified random sampling was used to split the data into independent training (N=153) and validation (N=117) subjects. Multivariate Cox Proportional Hazard and Proportional Odds models were used to model OS and PFS as a function of the pre-defined Singula TRI and clinical thresholds. Cox Proportional Hazards (PH) regression and likelihood ratio (LR) tests were used on the independent validation subjects to assess the hypothesis that Singula is predictive of OS and PFS above and beyond standard clinical factors.

Results

Using Cellworks Personalized Therapy Biosimulation, Singula TRI was significantly predictive of OS and PFS in univariate analyses and remained significantly predictive in multivariate analyses, which included patient age, patient sex, MGMT methylation status and drug class.

Conclusions

Cellworks Singula TRI facilitates selection of optimal personalized therapies by providing patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies. This information may be used to estimate increases in OS and PFS when comparing Singula TRI recommended therapies verses standard care. These positive results suggest the utility of biosimulation-informed therapy selection to improve survival of GEA patients.

About Cellworks Group

Cellworks Group, Inc. is a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology. Using innovative multi-omics modeling, computational biosimulation and Artificial Intelligence heuristics, Cellworks predicts the most efficacious therapies for patients. The Cellworks unique biosimulation platform is a unified representation of biological knowledge curated from heterogeneous datasets and applied to finding cures. Backed by UnitedHealth Group, Sequoia Capital, Agilent and Artiman, Cellworks has the worlds strongest trans-disciplinary team of molecular biologists, cellular pathway modelers and software technologists working toward a common goal attacking serious diseases to improve the lives of patients. The company is based in South San Francisco, California and has a research and development facility in Bangalore, India. For more information, visit http://www.cellworks.life and follow us on Twitter @cellworkslife.

All trademarks and registered trademarks in this document are the properties of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005437/en/

Barbara ReichertReichert Communications, LLC[emailprotected]415-225-2991

Michele Macpherson, Chief Business OfficerCellworks Group, Inc.[emailprotected]650-346-9980

Source: Cellworks Group, Inc.

Original post:
Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies - StreetInsider.com

The forums at analytica invite visitors to practical presentations and panel discussions.

Live in Munich again at last: When analytica, the worlds leading trade fair for laboratory technology, analysis and biotechnology, opens its doors from June 21 to 24, around 900 exhibitors will present their innovations. The industry is particularly looking forward to in-person dialog. There are ample opportunities for this at the trade fair stands, as well as at the analytica conference, in the forums and during the many other accompanying events. Nothing beats a real get-together, says Armin Wittmann, Exhibition Director for analytica. The attractive analytica supporting program brings the laboratory of tomorrow to life and facilitates the exchange of know-how, experience and ideas.

The analytica conference, the scientific high point of analytica, will take place on the first three days of the trade fair in the ICM, right next to the exhibition halls. Whether its nanoplastics, cancer diagnosis or antibiotic-resistant germs in the water cycle: In nearly 200 presentations and a poster show, renowned scientists from all over the world will discuss what modern analytics is capable of today, where its limits currently lie and how these can be overcome in future. The multifaceted program was put together by the German Chemical Society (Gesellschaft Deutscher Chemiker, GDCh), the German Biochemistry and Molecular Biology Society (Gesellschaft fr Biochemie und Molekularbiologie, GBM) and the German Society for Clinical Chemistry and Laboratory Medicine e.V. (Deutsche Vereinte Gesellschaft fr Klinische Chemie und Laboratoriumsmedizin, DGKL).

The megatrend of digitalization will be a common thread through the analytica conference program, as well as through the exhibition halls. In the Digital Transformation special show in Hall B2, visitors can experience automated workflows, networked devices and robots in action. In the neighboring forum of the same name, Agilent, Merck, Mettler Toledo, Thermo Fisher Scientific and many other companies will explain their concepts for Laboratory 4.0 in 30-minute presentations. The industry association SPECTARIS will provide an overview of the current status of a uniform OPC-UA interface for German manufacturers.

The Biotech forum (Hall A3), the Occupational Health and Safety forum and the analytica forum (both in Hall B1) likewise invite visitors to practical presentations and podium discussions. Among the highlights in the analytica forum are the expert rounds on COVID-19 research on June 22 and 23, with the likes of Professor Jonas Schmidt-Chanasit from the Bernhard Nocht Institute for Tropical Medicine in Hamburg and Professor Helga Rbsamen-Schaeff, Leopoldina member and founder and Supervisory Board member of the biopharmaceutical company AiCuris. The exact dates will be announced shortly on the analytica website.

The German biotech industry has emerged as a solution to problems during the pandemic and has collected more capital in the past two years than ever before. The Finance Days on June 23 and 24 at the Biotech forum in Hall A3 will cover financing trends in the life sciences sector and answer questions about initial public offerings and global markets. With the personalized medicine themed day on June 24, analytica is also putting a particular focus on this promising sector. Representatives from associations, clusters and companies in the health care sector will discuss the potential of individualized therapies from various perspectives.

Safety in the laboratory is the number one priority in day-to-day work. The Occupational Health and Safety forum in Hall B2 will be devoted to this topic. This year at analytica, the company asecos will once again demonstrate accidents that can happen if hazardous substances are stored incorrectly in the laboratory live in their daily experimental presentations. There will also be presentations on lithium-ion batteries that are increasingly finding their way into laboratories and whose potential dangers should they be mishandled are often underestimated. The program is rounded out by presentations from companies such as Erlab, Bernd Kraft and a1-environsciences.

Anyone who wants to use analytica as a career booster can combine a trade fair visit with further training. The training and consulting firm Dr. Klinkner & Partner will be offering all-day seminars at analytica on selected topics, from laboratory IT to the validation of analytical methods. And last but not least analytica, together with the scientific society GDCh and the VBio, will be supporting young talent in the industry. As usual, the popular student information day will take place on the last day of the trade fair on June 24. Here, high-school graduates can learn about fields of study and occupational areas in chemistry, biotechnology and food chemistry.

Read more from the original source:
Inspiration for the laboratory of tomorrow - Chemie.de

MarketQuest.biz latest record at the Global Nanomaterials in Personalized Medicine Market is predicted to experience excessive growth from 2022 to 2028. The report is an in-depth analysis of a wealthy supply of main factors liable for developing the global Nanomaterials in Personalized Medicine market. The study has captured several factors that have had or are having a substantial influence on the industry. The data factors like the drivers, flow patterns, openings, restrictions, and information are gathered through actual sources for plans for the Nanomaterials in Personalized Medicine market.

The Report Consists of:

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/125574

The report focuses on the studies of earlier and contemporary market attributes, which form a basis for evaluating the possibilities of the industry. The study assists in the identification of new marketing possibilities & provides a comprehensive view of the current global Nanomaterials in Personalized Medicine market. The record offers company profile of the key vendors operating in the Nanomaterials in Personalized Medicine industry and comparative analysis based on their business product offering, overviews, segment market share, business strategies, regional presence, innovations, joint venture, M&A, SWOT analysis, recent developments, collaborations, partnerships, and key financial information.

The worldwide Nanomaterials in Personalized Medicine market research is divided into categories that include

The global Nanomaterials in Personalized Medicine market study is classified into applications that cover

Some of the most promising vendors include:

ACCESS FULL REPORT: https://www.marketquest.biz/report/125574/global-nanomaterials-in-personalized-medicine-market-2022-by-company-regions-type-and-application-forecast-to-2028

The regional segments of the market include:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketquest.biz

View original post here:
Global Nanomaterials in Personalized Medicine Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2022-2028 Queen Anne and Mangolia...

ReportLinker

In-depth Analysis and Data-driven Insights on the Vendor Landscape, Competitive Analysis, and Critical Market Strategies are Included in this Global Biomarkers Market Report. Biomarkers are increasingly useful tools to predict prognosis and response to therapy in cancer patients.

New York, May 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biomarkers Market - Global Outlook & Forecast 2022-2027" - https://www.reportlinker.com/p06272725/?utm_source=GNW Furthermore, it allows to improve understanding of mechanisms of action and resistance to treatment.

The global biomarkers market is expected to grow at a CAGR of 11.44%.

KEY HIGHLIGHTS

Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth. As many healthcare settings have gained interest in personalized/precision medicine, many vendors have increased the studies focussing on identifying biomarkers to provide healthcare system solutions to them. Increasing focus on digital biomarkers will also drive the global Currently, several digital biomarkers are being tested for feasibility and reliability in Parkinsons and Alzheimers disease and clinical outcome assessments. Increasing discovery of epigenetic biomarkers for oncology is also driving the biomarker technologies market. There are more emerging companies increasing their research & development focus on discovering more epigenetics to diagnose various types of cancers. Technological Advancements in Biomarker Discovery are also positively impacting the biomarkers diagnostics industry. For instance, a recent development in portable biosensors allows rapid, accurate, and on-site detection of biomarkers, which helps prevent disease spread by controlling sources.

GROWTH ENABLERS

Increase In Number of Pipeline Biomarkers Rising Adoption of Biomarkers In Disease Diagnostics Technological Advancements in Biomarker Discovery

GLOBAL BIOMARKERS MARKET SEGMENTATION Oncology dominated the indication segment because biomarkers are being largely used for cancer research and diagnostics due to its high prevalence worldwide. Biomarkers in the field of oncology has revolutionized the diagnostics and treatment pathways.

Diagnostics dominated the application segment. However, the application of biomarkers in drug discovery & development is expected to grow significantly during the forecast period because biomarkers studies is expected to become an integral part of the drug development process with the aim of developing more effective drugs at a lower cost

Diagnostic biomarker dominated the type of segment as diagnostic biomarker studies have entered a new era where it holds promise for early diagnosis and effective treatment of many diseases.

Segmentation by Indication Oncology Cardiology Neurology Immunology Others

Segmentation by Application Diagnostics Drug Discovery & Development Personalized Medicine (PM) Others

Segmentation by Type Diagnostic Biomarker Monitoring Biomarker Prognostic Biomarker Susceptibility Biomarker Other Biomarker

VENDOR ANALYSIS Multiple companies partnering and investing in biomarkers research and development will help the companies to innovate new drugs and reduce the economic burden.

Key Vendors

Abbott company BioMerieux Biohit OYJ CENTOGENE Creative Diagnostics F. Hoffmann-La Roche company Fujirebio General Electric (GE) company TAmiRNA

Other Prominent Vendors

Accure Therapeutics Agilent Almac Group Applied Research Using OMIC Sciences (AROMICS) Bio-Rad Laboratories BioVision Caris Life Sciences Denovo Biopharma Dreamgenics Eisai Epigenomics Immunovia Insilico Medicine Lexogen Monument Tx Oryzon Genomics Plexision Rules-Based Medicine Siemens Healthineers Second Genome Therapeutics Thermo Fisher Scientific Ymir Genomics

GEOGRAPHICAL ANALYSIS North America dominated the geography because biomarkers have been in use highly for diagnostic purposes, drug discovery & development, and precision medicine. The increase in R&D expenditures and fundings for biomarker-driven drug discovery & development and precision medicine is one of the major driving factors in all the regions.

APAC is anticipated to exhibit the highest CAGR of 13.96% during the forecast period. Increasing developments and incorporation of advanced technologies to enhance the biomarker-based testing and increasing demand for biomarkers in drug development and personalized medicine are one of the primary factors in the region.

Segmentation by Geography

North America o US o Canada

Europe o Germany o France o UK o Italy o Spain

APAC o Japan o China o India o South Korea o Australia

Latin America o Brazil o Mexico o Argentina

Middle East & Africa o Turkey o South Africa o Saudi Arabia

THE REPORT INCLUDES: 1. The analysis of the global Biomarkers market size and growth rate for the forecast period 2022-2027. 2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global Biomarkers market. 3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities. 4. It offers a complete overview of market segments and the regional outlook of the Biomarkers market.Read the full report: https://www.reportlinker.com/p06272725/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Go here to see the original:
The global biomarkers market is expected to grow at a CAGR of 11.44%. - Yahoo Finance

Bioinformatics Marketis valued atUSD 10.82 Billion in 2021and is expected to reachUSD 24.07 Billion by 2028with aCAGR of 12.1%over the forecast period.

The increasing scope in research and development, drug discovery, new advancements in genetics analysis and synthesis methods and techniques are driving the Bioinformatics market.

The healthcare sector has seen a development in the last couple of years with the coronavirus pandemic hurting the world in the hardest ways possible and changing the way people live forever. Healthcare has been the topic of discussions at the macro and micro levels and manufacturers have realized that it is time for them to invest in technology and come up with innovative ways to help people. They get funded extensively with the government initiatives too as the authorities all over the world create commissions to help the healthcare sector. The research initiatives take time and multiple rounds of investment but in the interest of the people at large they make sure that those requirements are met. Bioinformatics market in healthcare depends a lot on how innovative the advancements are and how they are used in the long run as the lock in period is always going to be long.

A trend which is aiding Bioinformatics market in healthcare is the habits of people which are increasingly becoming unhealthier. People, particularly in the developing countries live a life where they work really hard and they do not have the time to focus on their health. That is why there is a rise in number of obesity and other diseases in the world. With technological advancements, many illnesses can be diagnosed before they become serious ailments. Diabetes is a common illness which can now be tapped by checking the blood sugar levels at home through advancements of technology. The technological advancements in Bioinformatics market in healthcare can also help people get healthcare services remotely. It is difficult particularly in the developing nations to manage time for their healthcare requirements. This has increased the prevalence of illnesses that made the world look at innovative ways to come up with solutions. In the pandemic, we saw that testing kits played a key role in preventing the spread of the pandemic.

Download Free Exclusive Sample (200 Pages PDF) Report @ :

https://brandessenceresearch.com/requestSample/PostId/1221?utm_source=nandini&utm_medium=mn

Some major key players for global Bioinformatics market are,

Bioinformatics market in healthcare has now seen its future vision and how the world will operate once the pandemic is over. Technology is going to play a key role in how the world moves forward. The challenges are going to increase only with the eating habits increasingly becoming worse. Healthcare sector has also been focusing on the mental health aspect. There are innovative ways where counseling can be given online with the use of technology. Governments are also focusing on finding means of e-healthcare in order to benefit people remotely. E-healthcare has also been aided by the accessibility of social media to the deepest part of countries.

The growth of literacy and awareness is also helping people get their consultancy online. The COVID pandemic showed the world ways in which adoption of technology can be the key to how countries deal with healthcare emergencies. Another factor which is aiding growth is how the insurance is extending its wings to the online consultancy too. This will continuously aid the initiatives of online consultancy and help the healthcare sector see growth in the coming years. Bioinformatics market in healthcare surely has a future which will depend on technological advancements

Bioinformatics Market: Key Features

The report throws light on the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the Bioinformatics market. Bioinformatics Market Size, Growth Analysis, Industry Trend, and Forecast, offers details of the factors influencing the global business scope. This report provides future products, joint ventures, marketing strategy, developments, mergers and acquisitions, marketing, promotions, revenue, import, export, CAGR values, the industry as a whole, and the particular competitors faced are also studied in the large-scale market.

Bioinformatics Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The data points provided are only related to the companys focus related to Bioinformatics market. Leading global Bioinformatics market players and manufacturers are studied to give a brief idea about competitions.

Latest news and industry developments in terms of market expansions, acquisitions, growth strategies, joint ventures and collaborations, product launches, market expansions etc. are included in the report. The report focuses on the operation and their competitive landscape present within the market. Identification of numerous key players of the market will help the reader perceive the ways and collaborations that players will need to understand the competition within the global Bioinformatics market.

Bioinformatics Market report provides depth analysis of the market recent developments and comprehensive competitive landscape created by the COVID19/CORONA Virus pandemic. Bioinformatics Market report is helpful for strategists, marketers and senior management, And Key Players in Bioinformatics Industry.

Market Dynamics Of Bioinformatics Market

Global Bioinformatics market report has the best research offerings and the required critical information for looking new product trends or competitive analysis of an existing or emerging market. Companies can sharpen their competitive edge again and again with this business report. The report comprises of expert insights on global industries, products, company profiles, and market trends. Users can gain unlimited, company-wide access to a comprehensive catalog of industry-specific market research from this industry analysis report. The market report examines industries at a much higher level than an industry study.

Table of Content: Global Bioinformatics Market Research Report

Chapter 1: Global Bioinformatics Industry Overview

Chapter 2: Global Economic Impact on Bioinformatics Market

Chapter 3: Global Market Size Competition by Industry Producers

Chapter 4: Global Productions, Revenue (Value), according to Regions

Chapter 5: Global Supplies (Production), Consumption, Export, Import, geographically

Chapter 6: Global Productions, Revenue (Value), Price Trend, Product Type

Chapter 7: Global Market Analysis, on the basis of Application

Chapter 8: Bioinformatics Market Industry Value Chain

Chapter 9: Bioinformatics Market Chain, Sourcing Strategy, and Downstream Buyers

Chapter 10: Strategies and key policies by Distributors/Suppliers/Traders

Chapter 11: Key Economic Indicators, by Market Vendors

Chapter 12: Market Effect Factors Analysis

Chapter 13: Global Bioinformatics Market Forecast Period

Chapter 14: Future Of The Market

Chapter 15: Appendix

Substantial research & development activities carry out by some players that comprises offering training to covering recent information on new technology, materials and techniques to innovative practice solutions, will complement the market growth is also explained. Frequent technological advances, superior portability, and ease of handling for Bioinformatics are boosting adoption in home and alternate care settings as well. Furthermore, non-profit and government initiatives, and awareness programs, and an influx of funding for research studies have positively influenced developments within the industry.

Global Bioinformatics Market: Regional Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2022 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact Us:

Contact No.: +91 7447409162, +44-2038074155, 1-888-853-7040

Email: sales@brandessenceresearch.com

Related Report

TheSilicon Photonics Market Valueis expected to record a valuation ofUSD 7253.6 Millionby 2028, Registering to Accelerate at a 25.8% CAGR, According to the most recent study by Brandessence Market Research & Consulting Pvt ltd.

TheAutomotive Diagnostic Scan Tools MarketValue is expected to record a valuation ofUSD 46.17 Billionby 2028, Registering to Accelerate at a 5.2% CAGR, According to the most recent study by Brandessence Market Research & Consulting Pvt ltd.

TheCRM Software Market Sizeis expected to record a valuation ofUSD 100.63 Billionby 2028, Registering to Accelerate at a 12.34% CAGR, According to the most recent study byBrandessence Market Research & Consulting Pvt ltd.

TheFrozen Potato MarketValue is expected to record a valuation ofUSD 81.69 Billionby 2028, Registering to Accelerate at a 4.12% CAGR, According to the most recent study by Brandessence Market Research

Originally posted here:
Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular...

Melanie Street calls COVID-19 a lion inside of my body.

When she was first infected with SARS-CoV-2 in January 2021, just two days before she had an appointment to be vaccinated, the virus hit her nervous system hard. For 23 days, she was in intense pain. She felt like she was choking, that her throat and mouth were swelling, and that she couldnt breathe.

It was very painful, like I was being attacked and played with, like a small toy. That's how I describe the waves of pain and the movement of the virus around my body, says Street, who lives in Flagstaff with her son.

After the acute infection, Street still experienced debilitating symptoms for months. Now, about a year later, those symptoms ebb and flow, but she has still had to give up all the physical activities she once loved. She has chronic fatigue that flares up whenever she exerts herself, causing a tension at the base of her skull, brain fog and pain that reverberates through her body.

Its just going on for so long for me, and it's so impactful, and it's terrifying, at a time when the sleeping lion likes to wake up and scratch around, she said.

Viral facts

The phenomenon we currently know as long COVID highlights a vexing reality of many viral infections: Some people develop serious or chronic symptoms when most others do not.

A recently confirmed connection between Epstein-Barr virus, which infects many people, and multiple sclerosis, which afflicts only a few, is another example.

Proving that link lies in confirming a temporal connection in other words, showing definitively that the viral infection happened before the onset of the disease. That can take a generation to confirm.

Whether or not someone develops severe symptoms related to a viral infection also may depend on other factors such as the microbiome and genetics.

While research raises the prospect of better treating viral infections, researchers note a lack of access to basic health care may still be the greatest barrier.

Streets son, a teenager, was ill with COVID-19 too in fact, Street thinks she got the virus from him. He had some persistent symptoms as well, but they were completely different. He had bouts of swollen glands and rashes, but nothing like the fatigue that sidelined his mother from her work, hobbies and outdoor activities.

Why did her sons version of long COVID, as she calls it, look so different than her own? Street wants to know. I just think that's what science is going to catch up with ... How the body reacts differently, she said.

Its a question that has long intrigued scientists who study all kinds of viruses, particularly latent viruses the ones that infect nearly everyone, often when we are children, and then stick around in the body for the rest of our lives. Often they are asymptomatic, and we never even notice theyre there. But new research suggests that there might be more late-onset and damaging effects associated with latent viruses than some scientists initially thought.

In one pioneering study this January, researchers at Harvard found a causal link between Epstein-Barr virus (or EBV, which most people contract, and which gives a few unlucky individuals mononucleosis) and multiple sclerosis (MS). The study, which has been over 20 years in the making, has implications for what may one day be revealed about long COVID, said Elizabeth Jacobs, a professor of epidemiology and biostatistics at the University of Arizona whose team has already begun studying COVID-19 long haulers.

We're expecting decades, decades of research on this, she said.

Although the mechanisms of SARS-CoV-2 are different from those of true latent viruses the coronavirus might not stick around in the body as long as or in the same ways as, say, EBV scientists are looking at reactivation of latent viruses, and other existing post-infection syndromes, for answers about long-haul COVID-19. For long haulers, for sure, I can tell you that we're going to be looking at other viruses, said Dr. Janko Nikolich-ugich, the head of the immunobiology department at the University of Arizona and co-director of the Arizona Center on Aging.

Nikolich-ugich, who is also part of a team that recently received a $9.2 million grant to study long COVID, said that he and other researchers are interested in examining the relationship between long COVID and latent viruses because it is probably the interplay between the host and the viruses that will determine why one person got (long COVID) and the other person just sailed through, he said.

But uncovering temporal and causal connections between latent viruses and long COVID could take a while. Thats why scientists are looking to existing knowledge, like the recently-confirmed connection between EBV and MS, for a glimpse of the future.

Virus case file: SARS-CoV-2

Commonly known as: Novel coronavirus, COVID-19.

What it is: RNA virus in the coronavirus family.

How you catch it: Breathing in the respiratory droplets of an infected person. Researchers are still investigating the extent to which airborne and surface transmission also play a role.

What happens first: While some infections are completely asymptomatic, others cause a range of symptoms including fever, cough, loss of smell and taste, body aches, fatigue, brain fog, and in more severe cases, hospitalization and death.

The latent phase: SARS-CoV-2 is NOT a latent virus. However, some researchers have begun to suggest that viral reservoirs can persist in some people for several months after infection in various tissues throughout the body.

What happens later: Some patients experience months- or even years-long symptoms that have been collectively described under the umbrella of long COVID. These wide-ranging and highly individualized symptoms include conditions like severe fatigue or intolerance to physical activity, persistent brain fog, extended loss of or changes in smell and taste, chronic pain, cardiovascular or GI issues and more.

What else it might be causing: Too early to tell.

Treatment/vaccine status: Several effective vaccines are available, as well as a preventative monoclonal antibody cocktail for the immunocompromised. Treatments include new antivirals and monoclonal antibody infusions. Not all treatments/vaccines are as effective against the omicron variant as they are against other strains.

Just over 20 years ago, Kassandra Munger, now a senior research scientist at Harvard, was working on her Masters in epidemiology when she started getting interested in MS research. As a relative of someone with MS, she wanted to learn more about the causes and risk factors for the disease. By 2001, Munger and a colleague had published a paper in the Journal of the American Medical Association establishing a link between higher levels of EBV antibodies and increased risk of MS.

But they needed more evidence to prove there were temporal links between EBV and MS in other words, that EBV infection itself happens before the onset of MS.

So for two decades, Munger and her team collaborated with the U.S. military, using a cohort over several years that numbered over 10 million people. With a population that size, they were able to find what they really needed a group of people who, when they were first identified and tested, had not yet contracted EBV. Most of that group were younger than 20 years old at the time of their first blood samples.

The researchers found that 34 of 35 individuals who were EBV-negative at the beginning and developed MS during the study had contracted EBV about 5 to ten years before the onset of MS. All 766 other individuals in the cohort who developed MS were EBV-positive before the study, too, meaning that 800 out of 801 individuals total who developed MS were previously infected with EBV.

Munger said that its not clear exactly whats going on with the one EBV-negative case, but since MS is a collection of symptoms and there is no one laboratory test to diagnose the disease, its possible that person was misdiagnosed or that other factors were contributing to their symptoms.

The researchers also tested the association with over 200 other viruses, including over a dozen latent viruses, and found that EBV was the only virus for which those who developed MS had higher antibody levels than controls.

MS is a rare disease, and not everyone who gets EBV will get MS. But the temporal link shows that, in the vast majority of cases, EBV is necessary for MS.

Thats a tangible place to start looking for solutions, and one of those would be obvious: vaccination. If MS almost never occurs without first contracting EBV, a vaccine for the virus should help prevent the later disease. Moderna, which made one of the most effective COVID-19 vaccines, has already started testing an EBV vaccine in clinical trials.

But beyond vaccines, the findings are a solid starting point for understanding the relationship between viruses and long-term effects in our bodies later in life.

Whats more, when they looked at EBV in relation to other viruses, Munger and her team found another fascinating relationship. Among individuals who had EBV, those who had also been infected with cytomegalovirus (CMV) showed a decreased risk of developing MS. It was a finding consistent with existing research, but it still left them with more questions.

We have no idea what the biological mechanism would be. Maybe…there is some temporal relationship there, that maybe being infected with CMV first provides some sort of protection once you're infected with EBV, Munger said. So it's an interesting finding and clearly speaks to the complexity of this. It's easy in a headline to pull out, you know, EBV causes MS. But it's so much more complex than what that captures.

Virus case file: Epstein-Barr virus

Commonly known as: EBV, Infectious mononucleosis (mono), kissing disease."

What it is: DNA virus in the herpesvirus family.

How you catch it: Spread through bodily fluids, most commonly saliva.

What happens first: Often asymptomatic if infected in childhood; infections in teenage years or later in life sometimes feature characteristic mono symptoms such as swollen lymph nodes, fatigue, fever, sore or inflamed throat. Occasionally causes rashes, an enlarged spleen or swollen liver.

The latent phase: After initial infection, resides for life in throat and blood cells.

What happens later: Initial mono symptoms can sometimes last for several weeks or months before EBV becomes dormant. Reactivation sometimes causes symptoms in people with weakened immune systems.

What else it might be causing: A recent 20-year study proved that EBV infection is necessary for the development of multiple sclerosis (MS) later in life.

Treatment/vaccine status: Moderna began Phase I clinical trials for an EBV vaccine this January. While there are no widely available treatments for EBV, stem cell treatments have been used for some chronic cases in immunocompromised patients.

Sources: my.clevelandclinic.org; ncbi.nlm.nih.gov; cdc.gov; hopkinsmedicine.org; cdc.gov; sciencedirect.com; biospace.com; academic.oup.com.

That complexity the dazzling abundance of viruses, cells, proteins, bacteria and even fungi that work together, uniquely, within each individual person means that researchers have to be strategic and extremely specific with their experimental design. Knowing what questions to ask, and where to go next with the answers, is part of the challenge. There's an art, sometimes, to the interpretation, Munger said.

She also noted that over the last 20 years, as the research community has become more open to investigating the long-term effects of viruses like EBV, she and her team has had the chance to build on scientific criticisms and find more definitive answers. Its an iterative process that she says will need to be expanded now that SARS-CoV-2 has arrived on the scene. She thinks scientists will need to ask big Q questions, as she puts it, about the relationship between the novel coronavirus, other viruses, and long-term illnesses like MS.

But for now, she expressed appreciation for the definitive results they do have on MS,results that could still be a long time coming for COVID-19.

It really does feel like the culmination of 20 years of work, like we've climbed Mount Everest, Munger said. Maybe we haven't quite reached the peak. There's still a lot that we don't know. But certainly it has been an incremental build over the past 20 years to get to the point where we are now.

When Jacobs heard about the results from Mungers team, she had a message.

In looking at data from our prospective cohort study of COVID19, the Arizona CoVHORT, I have mentioned a few times that some of the symptoms of LongCOVID harmonize with the ones I have with MS, she tweeted on Jan.13, along with a link to Mungers paper in Science.

For Jacobs, better known to her over 13,000 Twitter followers as @TheAngryEpi, the paper was not only relevant to her research on COVID-19 but also to her own experience with MS. She was first diagnosed with MS in 2003, following her sisters diagnosis, and she says that ever since she has done everything she can to minimize her symptoms, which include fatigue, muscle aches and spasms, double vision and vertigo, as well as more severe issues that have sometimes left her unable to walk for weeks at a time.

While disease-modifying drugs and exercise have helped her keep the most severe degenerative effects of MS at bay, Jacobs said that she has seen her experience of certain symptoms reflected in the testimonials of long COVID patients. Jacobs is part of the public health research study called the Arizona CoVHORT, in which over two dozen University of Arizona researchers have surveyed thousands of people across the state to learn more about the effects of COVID-19.

She says that as of this summer, among participants whose symptoms were followed for more than two months, as many as 77% of participants were still reporting symptoms of long COVID at six months.

Jacobs said that while she didnt want to falsely equate long COVID and MS, she says the results she and her team are beginning to see amplified her concerns over the long-term effects of COVID-19 that still remain to be studied. What it did was break my heart, because I know those symptoms very well, and I was really hoping others would not be experiencing it, she said.

Its a concern that other scientists share. I would be surprised if there were no longer-term sequelae (consequential conditions) of COVID-19, but only time will tell at this point, Munger said.

In the meantime, Jacobs described her hope for long COVID advocates to keep sharing their experiences, because she has already witnessed a pattern of dismissal of MS symptoms from within and outside of the medical community.

Anecdotally, I know people with MS who went years without getting a diagnosis where people would brush them off … I am very familiar with that sense of not being believed, Jacobs said. It's real. It's happening … Don't just assume right away that this is in their head or something because that is what (has been) done to a lot of MS patients for decades.

Its a pattern that other advocacy groups have also highlighted. Patients with myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS), Lyme disease and other post-infection syndromes have taken to social media and other online forums to share their calls for further research and support from the medical establishment.

To that end, Jacobs said that the pandemic has brought together infectious disease and chronic disease epidemiologists, which has had an accelerating effect on collaborative efforts to better understand the long-term effects of SARS-CoV-2. Its a research area that is not only booming but also growing, changing and gaining more acceptance and more funding.

Before we were more siloed, she said. COVID in our case has made (interdisciplinary teamwork) more seamless than it was in the past.

Street doesnt know whats causing all of her symptoms. But she does worry about how long they have lasted, and what that could mean for her body in the future.

(Im anxious because) I'm not sure if the virus is sitting within me, Street said. Is it sitting in my system? Is it going to come back five years from now? That part could be terrifying if you sit and think about it too long.

Still, she added that she tries to stay positive and move on with her life as best she can. Shes working part-time now, some of her symptoms are getting better, and she has found some relief through acupuncture several times a week. Recently, after 13 months, says that an osteopath diagnosed her with costochondritis, or inflammation of the cartilage that connects the ribs to the breastbone. While she says that the diagnosis doesnt take the issue away, she is relieved to have more information.

She has also signed up to participate in the University of Arizona CoVHORT study as well as a study on long COVID sponsored by the National Institutes of Health (NIH), as she waits for more answers.

Those answers could be different for her than for others with long COVID, explained Amy Proal, a microbiologist at the PolyBio Research Foundation, in a webinar where she discussed potential biological factors contributing to long COVID, including latent virus reactivation and dysregulation of the microbiome. According to Proal, the condition may very well represent a continuum of different effects within the body.

In one person, for example, a reservoir of SARS-CoV-2 may lurk in the intestinal tissue, sending inflammatory signals to the brain and resulting in sickness, nausea or other nervous system symptoms. While scientists still arent sure exactly how long the virus might persist in the body, a recent preprint from a team at the National Institutes of Health and other institutions suggests, based on autopsy data, that SARS-CoV-2 RNA might persist in the bodies of some patients for months.

But in another person, the coronavirus could have been cleared from the body, and yet it may have also caused a reactivation of Epstein-Barr virus in the process and disrupted the microbiome eventually resulting in those same or similar sickness, nausea and nervous system symptoms.

A takeaway is that if the same circuitry is being impacted, no two long COVID patients have to have the exact same mix of pathogens or inflammatory issues to develop these same sets of common symptoms, Proal said.

Its an idea that has been relevant to several other conditions in the past, but is only now being thrust into the limelight, said Michael VanElzakker, a neuroscience researcher at Massachusetts General Hospital and Harvard Medical School who worked with Proal to outline a list of biological factors that could lead to long COVID.

VanElzakker previously specialized in studying the long-term consequences of acute infections years and years, as he puts it, of trying to convey that some people don't fully recover from apparently infectious illness…and just trying to get it taken seriously.

He described how many poorly understood autoimmune conditions may really be a consequence of the immune system trying to get at something that was doing damage. He echoed the connections some advocates and researchers have drawn between long COVID and other conditions like Lyme disease, MS, and chronic fatigue syndrome, noting parallels in the ways some physicians have dismissed the so-called vague symptoms patients with those diseases often report.

VanElzakker added that many of those symptoms are actually clear markers of the immune response, and that breaking down the artificial barriers scientists have drawn between the nervous system and the immune system could lead to breakthroughs that address the root causes of many diseases root causes that might look different from person to person.

Its probably … going to take, you know, some thoughtful, genuinely personalized medicine to figure out what's happening in each person, he said.

Its a topic Jacobs has been bringing up in her classes as she asks students to wrestle with questions of justice and healthcare. Personalized medicine is like the bells and whistles, super space-age-like medicine … but it does ignore what to me is the biggest problem in health care right now, which is lack of access, she said. Poverty, for example, is a carcinogen. … I actually believe that (improving access) would be more effective in the next decade than personalized medicine.

VanElzakker observes similar disparities related to his own work, which he thinks will have implications for the kinds of care and support different patients will be able to receive in the future. This is one of the things that's both really invigorating and frustrating about research, he said. We're working on some amazing ways to test tissues. … But the idea that (someone without health insurance or adequate resources) that has long COVID is going to have access to that kind of stuff? Not for a while, not unless there's a big change.

While they wait for that change, long COVID patients like Street have taken to social media and to grassroots movements like Survivor Corps, an online network, to find community. Street still says she has felt isolated at times, because no two experiences with long COVID are the same. That parts quite lonely, she said.

But with those unique symptoms come opportunities for better research and care, and VanElzakker is hopeful that the flood of data and innovation that COVID-19 has initiated will make waves in a field that he has been part of for a long time.

It is a really promising moment, VanElzakker said. Because SARS-CoV-2 is new, there's a space for discovery.

Melina Walling is a bioscience reporter who covers COVID-19, health, technology, agriculture and the environment. You can contact her via email at mwalling@gannett.com, or on Twitter @MelinaWalling.

Independent coverage of bioscience in Arizona is supported by a grant from the Flinn Foundation.

Link:
Link between EBV and MS may give clues to the cause of long COVID - The Arizona Republic

In many areas of bioprocessing, cell adhesion and detachment pose fundamental challenges. Personalized medicine and other novel biomedical applications require the cultivation and handling of cells that mainly adhere on surfaces, says Katja Uhlig, PhD, a group leader at the Fraunhofer Institute for Cell Therapy and Immunology in Potsdam, Germany. So, cell attachment plays a crucial role in successful cell expansion. The cells must also be easily detached from the culturing surface.

Nonetheless, the kind of cells being cultured dictates the best surface for adhesion and detachment. This diversity poses a challenge to technical solutions for new surfaces that promise broad applicability for various cell types, says Uhlig.

Katja Uhlig, PhD. [Katja Uhlig (iklick photo studio)]Thermoresponsive polymers offer a promising coating. With thermoresponsive polymer coatings, cultured cells can be detached from a substrate within 30 minutes just by changing the temperature from 37C to room temperature. Plus, thermoresponsive polymer coatings provide two main advantages over conventional enzymatic digestion.

First, the membrane proteins are not digested, so the treatment is gentler on the cells, Uhlig explains. Second, there are fewer process steps since rinsing and inhibition of the enzymes are omitted. These advantages could improve the efficiency of cell cultivation on a larger scale, such as in bioreactors.

Although thermoresponsive polymer coatings are not new in cell culture, Uhlig points out that the coating procedures have been too complicated and costly to replace standard methods. To address those concerns, Uhlig and her colleagues spray the thermoresponsive polymer on conventional cell-culture materials. That makes the process inexpensive and flexible to use, she says.

To put this method into commercial bioprocessing, the synthesis of thermoresponsive polymer coatings must be scaled up and the spray-coating process must be automated. Still, Uhlig says: We hope that our contribution will modernize cell culture and make the process easier and gentler for the cells.

Read more:
Improving Cell Cultures with Thermoresponsive Coatings - Genetic Engineering & Biotechnology News

Since its onset, COVID-19 has been the focal point of recent healthcare innovation and advancement. Though the past couple of years have been filled with innumerable advancements of health technologies, much opportunity for reevaluating, reimagining, and reinventing the future of healthcare remains. The next two years will set the scope for what is to come.

Technology will be the driver behind innovation that refocuses healthcare on patient experiences and ... [+] navigation.

As our world successfully transitions from a pandemic to endemic stage, the landscape of healthcare innovation is wide-open for disruption, as health, wellness, and healthcare are taken more fundamentally into the digital age. Advancing technology will be the vigorous driver behind a much needed refocusing of healthcare delivery to put the patient experience and navigation of health services back where it belongs front and center.

What we can expectat least in the near-term futureis more digital transformation, more cloud, more integration, more automation, and overall a more coherent, consistent, and comprehensive delivery of healthcare.

Though the endless number of possibilities are inspiring, here are six areas where I foresee the most disruption occurring:

1. Integrating Health Technology and Big Technology: In the past, the merger between these two entities has been subject to many false starts. Big tech companies have been running at health technologies as quickly as they can, but last year we saw this trend finally take hold. Oracle ORCL acquired the nations second largest electronic health record vender; Microsoft MSFT unveiled plans to integrate Teladoc Healths TDOC clinical platform within its own Teams program; and Amazon AMZN integrated a wellness platform (Amazon Care) that offers employees healthcare services 24/7, 365 days a year. Google GOOG has revealed a new tool for clinicians that compiles health records across a wide range of electronic health record systems. This integration will prompt countless innovationsall unified by their power to simplify the patient experience.

2. Refocusing on Consumer Wellness Products: Consumer retail wellness products have taken off. A recent report claimed consumer spending has increased across wellness retail products, stating, US consumer spending on wellness categories including fitness, nutrition, appearance, sleep, and mindfulness, is increasing, as about 40% of US consumers consider these categories to be a high priority. The pandemic certainly helped to grow this space, especially for health technology companies that targeted individual wellness such as Peloton, Oura, and Headspace. This disruption appears to be here to stay, at least for the near future.

3. Doubling Down on Click and Mortar Hybrid Models: The pandemic made virtual health a necessity, and, as patients gained experience with this delivery model, virtual care has become a preferred method for many. In February the Department of Health and Human Services contributed $55 million to increase adoption and utilization of virtual health and reimagining how traditionally underserved populations access care. Virtual and In-Person hybrid modelsdubbed click and mortar modelscombine the benefits of virtual with in-person care, depending on the level of specific need at any given time. This allows for healthcare to be delivered when and where it is needed, reducing patient burden both from a convenience and cost perspective. Ultimately, this reimagining of healthcare delivery results in more accessible, personalized medicine and a better patient journey.

4. Revolutionizing Home Care: Inspired by the success of virtual care, the ability to offer patients treatment from the comfort of their own homes is revolutionizing quality of care and accessibility. This is especially true for Medicare fee-for services and Medicare Advantage beneficiaries, who, during the pandemic, were able to transfer many of their needed services out of healthcare facilities and into the home. It is a trend that is only growing, and, in the next three years, it is estimated this demographic will transfer nearly $265 billion worth of healthcare services to home settings. This reinvention of services is centered on quality and comfort, minimizing transportation and other access barriers, and outsourcing many clinical services from hospital buildings.

5. Accelerating Artificial Intelligence (AI) and Automation: Like the merging of health tech with big tech, AI in healthcare historically has been overhyped. But, its time, too, has come. AI and automation allow for health systems and practitioners to remove the tasks that humans do not have to do, such as patient monitoring, scribing, and many administrative duties. I foresee this having the most impact on administrative costs, which are at least 15% of our total healthcare expenditure in the U.S. (and this rate is growing 2.5 times faster than for comparable countries). Moreover, over half of our administrative costs are considered as waste. AI is already making a difference in reducing labor intensive tasks that contribute to burnout and in speeding up imaging processing to deliver faster care. There is a real opportunity here to make our healthcare system more efficient and affordable, and the tandem of AI and automation will fuel this disruption.

6. Building More Sustainable Healthcare Systems: Climate change is being heavily contributed to by the very entity we turn to when suffering climate-related illnesshealthcare systems. Our healthcare sector in the U.S. has been one of climate changes greatest accelerators: it is responsible for nearly 7,000 tons of waste a day, and for 10% of our countrys carbon emissions and 9% of air pollutants. Collectively, our healthcare sector is the 13th largest producer of carbon dioxide in the world. Innovation of the healthcare industry will result in a reevaluation, reimagining, and reinvention of sustainable efforts to protect patient health beyond the examination room. Kaiser Permanente is a leader in this field right now, having been carbon neutral since 2020 and aiming to be carbon net positive by 2025. They estimate their efforts are equivalent to taking 175,000 cars off our roads a year. We will see more and more players pledging carbon neutrality over the next few years.

The future of healthcare is undoubtedly more patient-focused, more virtual, more automated, and more environmentally minded. Disruption will see a necessary doubling down on investment in technologies and organizations dedicated to reimagining a more affordable, more convenient, more sustainable, and more comprehensive patient journey. At the end of the day, this is what healthcare is all about: making sure that we are providing the patients we serve with the best care possible.

Health reimaginings and reinventions are ripe with opportunities that will better quality of care and outcomes for all patients, allowing each and every one of us to live better, more fulfilling lives. The six areas above are worth paying attention to, setting the landscape as we all work in our own ways to improve health and wellbeing.

Visit link:
Reevaluating, Reimagining, And Reinventing Healthcare: Innovation In A Post-Pandemic World - Forbes

Scientists have studied the full genetic information of more than 18,000 cancer samples. They found new information about the patterns of mutations, or changes, that could help doctors provide better treatment.

Their study, which appeared recently in the publication Science, is not the first to do such a complete genetic study of cancer samples. But no one has ever used such a large sample size.

Serena Nik-Zainal of the University of Cambridge was part of the team that did the research. She said this was the largest cohort in the world. It is extraordinary."

Over 12,000 samples in the study came from patients recruited by Britains National Health Service. They were part of a project to study whole genomes from people with common cancers and rare diseases. The rest of the data came from existing cancer data sets.

Researchers were able to study such a large number because of the same improvements in technology that recently permitted scientists to complete the map of the entire human genome.

Andrew Futreal, a genomic expert at MD Anderson Cancer Center in Houston, was not involved in the study. He said the study gives scientists some knowledge of the destructive forces that cause cancer.

Cancer is a disease of the genome or full set of instructions for running cells. It happens when changes in a persons DNA cause cells to grow and divide uncontrollably. DNA is a substance that carries the genetic information in the cells of living things, like a human. In 2020, there were about 19 million new cancer cases worldwide.

For the study, researchers looked at 19 different kinds of cancer in the human body. It identified 58 new mutational signatures, or pieces of evidence leading to the causes of cancer. Nik-Zainal said researchers also confirmed 51 of more than 70 previously reported mutation patterns. Some arise because of problems within a persons cells; others are caused by ultraviolet radiation, tobacco smoke, or chemicals.

Knowing more of them helps us to understand each persons cancer more precisely, which can help guide treatment, Nik-Zainal said.

Genetic sequencing, the process used to study the makeup of a cell, is already being included in cancer care. It is part of the growing move toward personalized medicine, or care based on a patients genes and specific disease. Now doctors will have much more information to draw from when they look at individual cancers.

To help doctors use this information, researchers developed a computer program that will let them find common mutation patterns and seek out rare ones. Nik-Zainal said doctors could suggest a treatment based on a special pattern.

Futreal said the data can also show doctors what tends to happen over time when a patient develops a cancer with a certain mutation pattern. This will help doctors give earlier treatment and hopefully stop the developing disease.

Im John Russell.

Laura Ungar reported on this story for the Associated Press. John Russell adapted it for VOA Learning English.

____________________________________________________________________

sample n. a group of people or things that are taken from a larger group and studied, tested, or questioned to get information

pattern n. the regular and repeated way in which something happens

mutation n. a change in hereditary material

cohort n. a group of individuals having something (usually a statistical factor) in common in a study

genome n. the complete set of genes in a cell or organism

DNA n. a substance that carries genetic information in the cells of plants and animals

Read more:
Study of Cancer Genetics to Help with Targeted Treatment - VOA Learning English

By Amit Chopra

The field of molecular diagnostics has witnessed a period of rapid development and growth in the last decade. The introduction of new technologies and the implementation of highly accurate tests into clinical testing protocols have been pivotal in advancing the field of precision medicine.

The pandemic has dramatically accelerated this growth, and this momentum is likely to continue into the post-pandemic phase. As per industry sources, the global molecular diagnostics market size was valued at USD 36.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.9% from 2021 to 2028. Likewise, the Indian molecular diagnostics market stood at an estimated USD 920 million in 2020 and is projected to grow at a CAGR of around 10% till FY 2026.

The rapid spread of Covid has led to an expansion of the Molecular diagnostics testing infrastructure in the country. Furthermore, government initiatives to increase healthcare funding to improve the countrys molecular diagnostics capabilities will also positively impact the market in the coming years. Other influencing factors include higher demand for Point of Care (PoC) diagnostics, a rising elderly population, and a sustained increase in infectious diseases.

Rising Demand for Point of Care (PoC) Diagnostics

Point of care diagnostics solutions has emerged as a significant driver for the advancement of molecular diagnostics during the COVID-19 pandemic. Leading diagnostic companies have adopted advanced technologies like AI to deliver products that could make testing faster and more accurate. A rapid POC test based on gold standard RTPCR technology, Acula has revolutionized rapid and accurate Covid testing worldwide. The platform will also be used to scale and develop point-of-care tests for other infectious diseases in the future. With the onset of many other smart technologies which leverage IoT, AI and ML, we will likely see more innovative products for chronic and lifestyle conditions, including oncology.

New growth drivers including Government Initiatives

Before the pandemic, Real-Time PCR (RT PCR) was considered a very niche technology that only a handful of labs around the country could use. COVID-19 challenged our diagnostics industry to rapidly build their capabilities to a point where we have over 3000+ testing laboratories in India alone that perform molecular testing. With RT PCR, viral amplification, and genome sequencing becoming mainstream, the field of molecular diagnosis is set to be revolutionized. In addition, government funds and grants for developing novel products are also fueling the adoption of advanced technologies for infectious diseases diagnosis. In support of the Make in India initiative, Thermo Fisher Scientific introduced a manufacturing facility in Bengaluru, which produces CoviPath RT-PCR testing kits and MagMAX Dx Prefilled Viral/Pathogen Nucleic Acid Isolation kits that deliver faster, more precise, and easy-to-use Covid testing solutions.

Market expansion in new areas of science and research

Thermo Fisher Scientific mobilized its range of resources by making strategic investments fueling exciting opportunities in cell and gene therapy, companion diagnostics, liquid biopsy, direct-to-consumer, and more through product introductions, partnerships, and facility expansions.

Advancements in the field of Precision Medicine

The global understanding and practice of medicine are currently undergoing a revolutionary change. The shift to precision medicine means moving healthcare from a one-size-fits-all approach to a more targeted approach, where decisions are informed by each individuals unique clinical, molecular, and lifestyle information. Globally, we are closely working with the precision medicine community and helping advance this revolution in diagnosis and treatment by leveraging our global infrastructure and expertise to provide industry-leading capabilities, from population profiling to targeted therapeutics.

Wider adoption of precision medicine will usher in a new era for healthcare and diagnostics where patients receive the care they need, especially for life-threatening conditions.

A step in this direction is precision oncology using next-generation sequencing (NGS) technology that accelerates targeted therapy treatment selection and improves patient outcomes. NGS is involved throughout the development continuum for targeted treatments from translational research to companion diagnostics testing and has enabled personalized oncology to improve patient outcomes.

Molecular Diagnostics: Paving a new path for treatments

Molecular diagnostics is one of the most dynamic and transformative areas leading to advances in prognosis, research, and treatment. The pandemic has further highlighted the importance of this sector. With the support of academia, government, industry, and private companies, the field of molecular diagnostics is now set to enter a new phase that will unveil new-generation technology for modern-day practice and improved outcomes for patients.

(The author is Managing Director, India and South Asia, Thermo Fisher Scientific. The article is for informational purposes only. Please consult medical experts and health professionals before starting any therapy, medication and/or remedy. Views expressed are personal and do not reflect the official position or policy of the FinancialExpress.com.)

Original post:
Increased demand for Molecular diagnostics after the COVID-19 outbreak - The Financial Express

One of the next big shifts in patient care will be precision medicine will be"an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment and lifestyle for each person," as the Precision Medicine Initiative describes it.

For physicians and researchersthis means predicting more accurately which treatment and prevention strategies for a particular disease will work in particular groups of people.

This is completely different from the traditional one-size-fits-all approach, in which treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.

What does this mean for healthcare and health IT? A lot of new challenges. Because precision medicine and genomics generate massive volumes of varied and granular data, new approaches to data storage and exchangeand new designs for electronic health records,for example, may be required. Physician education and patient communication are two other areas that will demand attention

Some advanced healthcare provider organizations, such as large academic medical centers,are already well-advanced in their precision medicine efforts. But most providers are still early in the journey, if they're attempting it at all. But many are preparing today for what many think will be the next step in the evolution of healthcare.

This story, focused on precision medicine and other emerging technologies, is the sixth and final installment in Healthcare IT News' feature series, "Health IT Investment: The Next Five Years."

The series offers interviews with primarily CIOs to learn from them the path forward through the priorities they set with their investments in six categories: AI and machine learning; interoperability; telehealth, connected health and remote patient monitoring; cybersecurity; electronic health records and population health; and precision medicine and other emerging technologies. Click here to access all the features.

The six health IT leaders discussing their plans for the next five years in this sixth and final installment in the series include:

Precision medicine has been an organizational priority for UPMC for more than a decade, and it has an ambitious vision of using it to provide better, more personalized care and improved outcomes for patients.

"Through these efforts, we aim to create new insights into the drivers of health and disease to allow the discovery of innovative therapies and models of care, while also lowering the cost of care by avoiding diagnostic delays and therapeutic dead ends," said Kleinz of UPMC.

"As one of the largest integrated healthcare delivery and insurance organizations, UPMC has the scale, capabilities and ambition to lead the discovery, assessment and clinical deployment of impactful precision medicine approaches," he continued.

Dr. Matthias J. Kleinz, UPMC Enterprises

"Our efforts are led by the Institute for Precision Medicine, which was established in 2014 in collaboration with our academic research partner, the University of Pittsburgh."

The mission for the institute is to accelerate translational and clinical research in precision medicine and to deliver the most advanced prediction and treatment of disease, tailored to an individual's unique circumstances, history and condition.

"In this context, we have and will continue to make significant investments in established molecular and genomic tests [and]emerging proteomic, metabolomic, and microbiome assay technology, and drive the discovery of highly personalized precision therapeutic approaches, including cell, gene and regenerative medicines," Kleinz explained.

Investment in deployment and development of novel technologies is an important pillar inunlocking the value of precision medicine.

UPMC has made a number of significant initial investments in the following areas, Kleinz noted, and is continuing to evaluate new opportunities:

"UPMC's leadership strongly supports this vision and already has invested heavily in the implementation of precision medicine," he said. "The appropriate use of precision medicine approaches benefits first and foremost our patients, but also supports our providers as they deliver care across the UPMC system.

"The tangible benefits are streamlined clinical workflows, improved patient outcomes, and the potential to optimize resource allocation and reduce the long-term cost of care," he continued.

"We are dedicated to continuing the aggressive rollout of precision medicine, both through internal efforts and increasingly through creative partnerships with industry, such as our partnership with proteomics company Somalogic."

Sanford Health believes precision medicine will be the future of healthcare, so it continues to make significant investments in this space.

"Leveraging machine learning and high computational power to analyze data sets containing genetic, clinical and socioeconomic data will not only help design the best personalized treatment for our patients, but also will help identify those patients or patient populations that would benefit most from early screening and interventions to prevent disease," said Hocks of Sanford Health.

Matt Hocks, Sanford Health

"Precision medicine will allow us to concentrate our efforts on prevention and early screening, diagnosis, and care that will help keep our patients healthy and thriving for generations to come," he added. "Cancer care and chronic disease management are burdensome to patients, communities and health systems. Concentrating resources to prevent these conditions will benefit us all."

Mobile health is an area of health IT that has been emerging in recent years. The same with remote patient monitoring, which has especially gained ground during the COVID-19 pandemic. Virginia Hospital Center is on top of both.

"Virginia Hospital Center does not view itself as cutting-edge when it comes to technology," Mistretta said. "It considers itself more of a fast, early adopter of new technology it believes may provide an advantage to its patients.

"We are extremely patient-focused, so many of our investments moving forward are going to be in that realm," he continued. "We will be investing in hospital-at-home and remote patient monitoring features in depth, along with other patient engagement functions to empower our population and maintain low-touch care to minimize costs."

Mike Mistretta, Virginia Hospital Center

Mobility is in demand by patients, so connecting through web and app technologies will be a high priority, he added.

"We need to make care convenient for patients and provide care on their terms," he observed. "In our Northern Virginia/D.C. market, we hear about this frequently due to traffic and distance considerations."

Thus the development of pilot programs like the organization's OB Connect, where patients followed for maternity care are issued home equipment, post resultsand are able to skip the office if everything is within expected limits. Mistretta believes this kind of technology will permeate the market.

"These types of technologies will be required to sustain significant growth for health systems," he said. "Combined with the effective use of data to produce appropriate metrics, we should be able to pinpoint more specific markets and what treatments produce more effective outcomes.

"It also is the only way we will be able to meet the significant demands that will be placed on the care system with the shortage of nursing and primary care resources predicted to hit in the coming years," he added. "We simply will not be able to continue to experience the same results and levels of treatment enjoyed today as the population grows and ages without providing increased care outside the walls of our traditional organizational structures."

Leadership buy-in on a different approach will take some time, but with successes along the way (and supporting data to reinforce), healthcare organizations will be able to achieve what will be needed, he said.

Providence pledged to invest $50 million over five years in health equity. Here is a recap of how it invested in year one.

Elsewhere, Moore is concerned with the internet of things.

"The internet of things is it it's smart devices," he said. "We may give our patients smart devices that sit in our care delivery environments, and have the telemetry information, and go into our big data model. Because that's how we're really going to make these machine learning and artificial intelligence models shine.

B.J. Moore, Providence

"We in healthcare say big data, but until you're working with streams of data, it's not really big data, it's just large data warehouses," he continued. "So getting that remote care delivery data is important, like a temperature four times a day, or real-time streaming of oxygen or heart data."

Moore believes the IoT and the streams of data it can provide are things healthcare executives should be talking about more. "It's all about data volumes: The bigger the volume, the better," he said.

Regenstrief is in the process of developing tools and processes to identify bias in algorithms to improve health equity, said Grannis of Regenstrief Institute.

"As AI becomes more ubiquitous, researchers, clinicians, health systems, industry, government and others must be wary of unintended consequences," he stated. "Our research scientists are working on best practices as well as novel analytical tools to regularly monitor for bias in algorithms, a process Regenstrief and CEO Dr. Peter Emb have coined "algorithmovigilance."

"Over the next five years, Regenstrief will be working with individuals and organizations around the world to implement," he added.

Dr. Shaun Grannis, Regenstrief Institute

Regenstrief also is investing in the broader ecosystem required to sustain advanced AI and machine learning methods. In the same way that clinical decision-makers, including physicians and other care providers, undergo regular training updates and certification due to healthcare's evolving nature and potential for bias, advanced algorithms will need frequent updates and certification to minimize bias and or errors, Grannis said.

Frameworks for overseeing algorithms and analytics are nascent.Developing and evaluating approaches to accurately and efficiently monitor AI and machine learning will become increasingly important in the future of healthcare analytics, he added.

"We also are investing in patient ergonomics the application of human factors,engineering and psychology to the design and evaluation of patient-facing technology to enhance delivery of healthcare," he explained.

"Institute scientists are using user-centered design to create apps that help informal caregivers provide care for their loved ones with Alzheimer's and other chronic conditions. Other apps are exploring the benefits of specific diets and brain-stimulating games."

Babachicos of South Shore Health believes tools that assist patients with care navigation will allow for a more improved and directed patient experience.

"These tools combined with the next-generation call centers also known as patient access centers can be accessed 24/7 by patients looking for care options and direct patients to the right place at the right time for their care needs," she explained. "These patient access centers will use multichannel options such as text, voice and chat while allowing patients to perform many self-service functions, as well.

Cara Babachicos, South Shore Health

"These patient access centers might also be staffed by care navigators for a more human connection when necessary," she concluded. "The same centers could potentially deliver virtual visits/consults, as well as potentially manage patient medications and vitals for subscribed patients in the community."

Twitter:@SiwickiHealthITEmail the writer:bsiwicki@himss.orgHealthcare IT News is a HIMSS Media publication.

The rest is here:
CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News

MONTPELLIER, France--(BUSINESS WIRE)--SeqOne Genomics, provider of next genomic analysis solutions for personalized medicine today announced a Series A funding round of 20M.

The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease.

The company will intensify investments in the development of its genomic-aware data lake to improve the use of big data and machine learning approaches in genomic analysis with the aim of better addressing the fast-evolving needs of molecular biology labs that provide genomic analysis in clinical routine environments, as well as to biopharma companies developing new therapies.

SeqOnes cloud-based solution manages the entire genomic analysis process from raw data to final report presented to clinicians. The solutions end-to-end approach affords better analytic performance, high levels of traceability and improved operational efficiency and has already been adopted by a score of hospitals and central labs and biopharmas as well as spawning partnerships with leading manufacturers of genomics analysis hardware and reagents.

Nicolas Philippe, Ph.D., Co-founder and CEO of SeqOne Genomics stated We are extremely happy to have closed this round with leading investors who bring extensive experience in deep-tech, healthcare and biotherapy and who share our vision of building SeqOne into a global leader in personalized medicine. The funding will give us the resources we need to enhance and commercialize our solution to make genomic analysis more accessible and affordable so that each patient can benefit from personalized medicine recommandations.

The genomics analysis market is experiencing exponential growth driven by the needs of personalized medicine. With the rapid expansion in the available genomic-linked treatments, the complexity of treatment interactions, and the staggering volume of biological and medical data to be factored into each medical decision, biologists and doctors must have access to reliable and actionable analyses in real-time, stated Fabien Collangettes, Director at Omnes. We were particularly impressed by SeqOnes innovative technological approach that enables improved accuracy of genomic test while reducing turnaround time and cost, thus delivering a key competitive advantage in this fast-growing market.

With the closing of this round, SeqOnes board of directors will be: Sacha Loiseau, Ph.D. independent board member and Chairman of the Board, Fabien Collangettes, Director at Omnes, Yoann Bonnamour, Investment Manager at Merieux Equity Partners, Marc Rougier, Partner at Elaia, Nicolas Philippe, co-founder and CEO of SeqOne Genomics and Jean-Marc Holder, Co-founder and Chief Strategy and Innovation officer of SeqOne Genomics.

This new funding round brings the total amount raised by SeqOne Genomics since its founding in 2017 to 23M.

The company currently employs over 40 staff, primarily experts in genomic medicine, data science, bioinformatics, software development and regulatory compliance / quality assurance. It plans to double its staff within the year to execute its ambitious plans.

Advisors:

Legal:Anthony Beauquier - LSF AdvisoryJones Day - Jean-Gabriel Griboul and Hortense FouillandMarket intelligence : Clara Niarfeix Alcimed

Intellectual property: Claire Verschelde, PhD ICOSA

Financial due diligence : Crowe HAF Maxime Hazim and Julien Latrubesse

About SeqOne Genomics

SeqOne Genomics offers high performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company's proprietary GeniOS genomics operating system to dramatically reduce turnaround times and costs while delivering a comprehensive and actionable insights for personalised medicine. The company has won numerous awards including the iLab award and the ARC cancer foundations Hlne Stark prize.Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club.

Web: https://seqone.com Direct link to this release: https://seqone.com/seriesa

About Elaia

For more information: http://www.elaia.com @Elaia_Partners

About IRDI Capital Investissement

Learn more: https://www.irdi.fr/

About Merieux Equity Partners

For more precision: http://www.merieux-partners.com

About Omnes

For more precision: http://www.omnescapital.com

About Software Club

For more precision: softwareclub.io

Go here to read the rest:
SeqOne Genomics Closes 20M Series a to Accelerate the Deployment of Its Genomic Medicine Platform - Business Wire

BUFFALO, N.Y. A joint study conducted by researchers at the University at Buffalo and the University of California, Los Angeles is revealing for the first time that behavioral self-management of irritable bowel syndrome (IBS), a painful and common gastrointestinal disorder, can fundamentally change the gut microbiome. It is the first to show how cognitive behavioral therapy can teach patients information-processing skills that address the biological roots of their GI symptoms.

This work demonstrates that teaching people how to think more flexibly in specific situations can reduce the physical tension and stress that can disrupt brain-gut interactions and crank up symptoms, said Jeffrey M. Lackner, PsyD, co-senior author on the paper, professor in the Department of Medicine and chief of the Division of Behavioral Medicine in the Jacobs School of Medicine and Biomedical Sciences at UB.

Published late last year in the journal Microbiome, this study, conceived by an interdisciplinary UB team, shows how a non-drug, non-dietary treatment for IBS induces changes in brain function and in the microbiome by normalizing ways of processing information, Lackner explained.

These results will have a dramatic impact on understanding a gastrointestinal disease that has a significant public health burden, he said. This is paradigm-shifting for how we understand the role of the microbiome and therapeutics that can modify its composition to treat and prevent disease.

Emeran A. Mayer, MD, an internationally known expert on the interactions between the digestive and nervous systems, is co-senior author on the paper. He is a professor in the David Geffen School of Medicine at UCLA and executive director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience.

"Dr. Lackners collaborative project with UCLA is an important breakthrough in the understanding of how cognitive behavioral therapy can alter brain-gut interaction to provide relief for IBS patients, saysAllison Brashear, MD, UBs vice president for health sciences and dean of theJacobs School. This studys translational research provides new hope for those afflicted with this debilitating disease.

The study was funded by grants from the National Institute of Diabetes and Digestive and Kidney Diseases to Lackner and Mayer, UBs Office of the Vice President for Research and Economic Development and UBs Genome, Environment and Microbiome (GEM) Community of Excellence.

The findings are the first to demonstrate that a specific type of cognitive behavioral therapy developed at UB that teaches information-processing skills can modulate key components of the brain-gut-microbiome axis in some of the most severe IBS patients, said Lackner.

Learning-based treatments

We know that the gut microbiome is a key to regulating brain-gut interactions and plays a role in overall human health from metabolism to immunity. We also know learning-based treatments like cognitive behavioral therapy are some of the most robust treatments of any kind for what is the most prevalent GI (gastrointestinal) disease, even when they are home-based delivered with minimal doctor involvement, said Lackner.

What we didnt know is how those two facts interact, said Lackner. We didnt know whether symptom relief following CBT depends on the microbiome environment to achieve its effects.

This study is important because it reveals a precise microbiome signature that distinguishes patients who respond positively to a drug-free treatment and those who dont, and that signature corresponds with objective changes in brain function, he added.

The fact that we see patient-reported GI symptom improvements that correspond with objective biological changes in the microbiome and brain function is pretty remarkable given that we focused on a low-intensity, home-based behavioral treatment and not medical therapies like probiotics, prebiotics, postbiotics, antibiotics, and fecal microbiota transplantation known to manipulate our microbiome, Lackner said.

Eighty-four IBS patients were recruited from the parent CBT trial the Irritable Bowel Syndrome Outcome Study, a landmark, National Institutes of Health-funded clinical trial led by Lackner that has transformed the way IBS is understood and treated.

The 84 participants underwent neuroimaging and detailed clinical assessment at clinical sites at UB and Northwestern University. UB also collected microbiome data through fecal sampling from 34 of the patients.

Eligible patients were randomized to receive 10 sessions of clinic-based CBT or four sessions of largely home-based CBT with minimal therapist contact over a 10-week acute phase. Both treatments were developed at UB.

Boundary-breaking translational research

This trial was enormously complex in that we collected symptom data across different sites at pre-treatment and post-treatment, said Lackner, who sees patients at the Behavioral Medicine Clinic at UBMD Internal Medicine. Because we were also collecting biological data at multiple times, it required a high level of precision and project management unique among major research centers. It really speaks to our divisions capacity to support boundary-breaking, novel translational research with high impact potential.

UB partnered with the David Geffen School of Medicine at UCLA and the G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA.

All that data had to be expertly analyzed and that is where we were able to draw from the expertise of our long-standing collaborators at UCLA, experts in microbiome and imaging research, Lackner says.

UB developed the treatment, delivered it and collected data, while UCLA analyzed gut microbiome and neuroimaging data.

It is a great example of team science between two outstanding research facilities with unique synergies, Lackner says. Theres a lot of reasons why this type of study hasnt been done up to now, but we were able to leverage our unique clinical expertise and our clinical research infrastructure and UCLAs expertise.

Of the 84 participants in the trial, 58 were classified as CBT responders and 26 were classified as non-responders.

While there were small pre-treatment differences between brain network connectivity for responders and non-responders, the significant difference was how much the connectivity changed after treatment.

Responders showed greater baseline connectivity than non-responders between the central autonomic network and the emotional regulation network, according to the study.

Lackner said that the findings raise the possibility that CBT-responsive IBS patients can be identified in clinical practice using microbial biomarkers, before less effective treatments are initiated at great expense to the patient and health care system.

The pattern of data may explain normal versus abnormal gut function and just how the brain-gut can influence symptoms and the relief of them, Lackner says. Larger studies are needed to characterize the functional correlates of gut microbial changes and to identify distinct subtypes of IBS patients for whom brain- and gut-directed therapies are most effective.

This is an example of science moving away from a one-size-fits-all brand of medicine toward a more personalized medicine approach driven by translational research.

Jonathan P. Jacobs, MD, PhD, and Arpana (Annie) Gupta, PhD, both of the David Geffen School of Medicine at UCLA and the G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA, are the studys co-first authors.

Co-authors from the Jacobs Schools Division of Behavioral Medicine are:

Rebecca S. Firth, division administrator and research coordinator.

Gregory D. Gudleski, PhD, research assistant professor.

Other co-authors are from the following institutions:

David Geffen School of Medicine at UCLA.

G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA.

Imaging Genetics Center, Mark and Mary Stevens Institute for Neuroimaging and Informatics, Keck School of Medicine at University of Southern California.

Read more here:
Study: In IBS patients, cognitive behavioral therapy modulates the brain-gut microbiome and helps relieve symptoms - UB News Center